Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (301-310 of 477) with videos related to

Pageof 48
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2017
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid ArthritisMichael E Weinblatt, Clifton O Bingham, Gerd-Rüdiger Burmester, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Arthritis and Rheumatism|June 3, 2008
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler, Frank Behrens, David Pittrow, et al.
Rheumatology (Oxford, England)|July 11, 2013
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisDaniel E Furst, Jonathan Kay, Mary Chester Wasko, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2020
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic SclerosisVivek Nagaraja, Marco Matucci-Cerinic, Daniel E Furst, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2007
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange, Marcy B Bolster, Michael D Roth, et al.
Arthritis and Rheumatism|December 1, 2007
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysisEdward Keystone, Roy Fleischmann, Paul Emery, et al.
Rheumatology (Oxford, England)|June 1, 2016
Calcinosis in systemic sclerosis: subsets, distribution and complicationsFrancesca Bartoli, Ginevra Fiori, Francesca Braschi, et al.
Seminars in Arthritis and Rheumatism|October 23, 2016
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trialsSimon Tarp, Daniel E Furst, Anna Dossing, et al.
The Lancet. Rheumatology|January 30, 2024
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)Silvia Bellando-Randone, Francesco Del Galdo, Gemma Lepri, et al.
Pageof 48

Showing results (301-310 of 477) with videos related to

Sort By:
Pageof 48
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2017
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid ArthritisMichael E Weinblatt, Clifton O Bingham, Gerd-Rüdiger Burmester, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Arthritis and Rheumatism|June 3, 2008
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler, Frank Behrens, David Pittrow, et al.
Rheumatology (Oxford, England)|July 11, 2013
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisDaniel E Furst, Jonathan Kay, Mary Chester Wasko, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2020
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic SclerosisVivek Nagaraja, Marco Matucci-Cerinic, Daniel E Furst, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2007
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange, Marcy B Bolster, Michael D Roth, et al.
Arthritis and Rheumatism|December 1, 2007
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysisEdward Keystone, Roy Fleischmann, Paul Emery, et al.
Rheumatology (Oxford, England)|June 1, 2016
Calcinosis in systemic sclerosis: subsets, distribution and complicationsFrancesca Bartoli, Ginevra Fiori, Francesca Braschi, et al.
Seminars in Arthritis and Rheumatism|October 23, 2016
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trialsSimon Tarp, Daniel E Furst, Anna Dossing, et al.
The Lancet. Rheumatology|January 30, 2024
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)Silvia Bellando-Randone, Francesco Del Galdo, Gemma Lepri, et al.
Pageof 48